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There is increasing evidence that oncornavirus-like information is present in 
human cells. The bulk of this evidence rests upon reverse transcriptase studies 
(1-3), DNA-RNA hybridization homologies (4, 5), immunochemical analysis of 
viral-like antigens  in human tissues (6-8),  and the isolation of C-type viruses 
from human  tissues  (9-11).  Recently,  Mak  et  al.  (12)  and  Vosika  et  al.  (13) 
reported  that  some  human  marrows  in  culture-released  particles  with  some 
physical  and  biochemical  properties  resembling  those  of oncornaviruses.  We 
have undertaken to examine the immunological properties of particles obtained 
in similar marrow culture supernates, particularly with regard to (a) whether 
they contain determinants cross-reactive with mammalian RNA tumor viruses 
and (b) whether antibodies to such determinants occur spontaneously in human 
sera.  Internally  radiolabeled  material  from  marrow  culture  supernates  was 
used as antigen  in a  double-antibody immunoprecipitation  assay, and precipi- 
tated antigens were analyzed by sodium dodecyl sulfate (SDS) polyacrylamide 
gel electrophoresis. In this paper, we report that proteins similar to those of the 
major structural proteins of oncornaviruses can be identified in human marrow 
culture supernates, and that antibodies to these proteins are commonly present 
in human sera. 
Materials  and  Methods 
Patzent  Material.  Bone  marrow  specimens were  obtained from patients with  acute  myelo- 
blastic leukemia (AML), 1 acute lymphoblastic leukemia (ALL), acute erythroleukemia,  chronic 
granulocyte leukemia (CGL),  or nonleukemic patients undergoing hematological investigation. 
Human sera were aliquoted and frozen at  -70°C  until use.  Pooled normal human IgG and two 
purified IgG h-myeloma proteins were generously provided by Dr.  B.  Underdown,  Institute of 
Immunology,  University of Toronto, Toronto. 
Viruses.  M4 virus is a mouse leukemia virus spontaneously released by a clone of JLS-V9 cells 
in  culture  (14}. [3H]leucine  and  [14CJleucine-labeled  M4  virus  was  kindly provided  by  Dr.  A. 
Howatson of the Ontario Cancer Institute. 
* This work  was supported by the Medical Research Council of Canada,  the Ontario Cancer 
Treatment and Research Foundation, and the National Cancer Institute of Canada. 
1  Abbreviations  used  in this paper:  ALL,  acute lymphoblastic leukemia; AML,  acute myelo- 
blastic  leukemia;  CGL,  chronic  granulocytic  leukemia;  LCM,  leukocyte-conditioned  medium; 
RIPA,  radioimmunoprecipitation assay;  RLV,  Rauscher  murine leukemia  virus;  SDS,  sodium 
dodecyl sulfate; SLE, systemic lupus erythematosus; SSV, simian sarcoma virus. 
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Rauscher murine leukemia virus (RLV) was obtained from Electro-Nucleonics Inc., Fairfield, 
N. J., and simian sarcoma virus (SSV-1/NC 37) from Litton Bionetics, Kensington, Md. 
Marrow  Cultures.  Nucleated  marrow  cells from  buffy coat  preparations were cultured  in 
suspension in a-medium (Flow Laboratories, Inc., Rockville, Md.) for 5-7 days at 37°C in 5% CO2 
in air.  Culture  media contained 20%  fetal calf serum (Flow Laboratories) and  10% leukocyte- 
conditioned medium (LCM).  This LCM, prepared from peripheral leukocytes of a  patient with 
hemochromatosis, has  previously been described  (3). Before  use,  fetal  calf serum  was  spun 
overnight at  100,000 g  and  then heat  inactivated at  57°C for 30  min.  Gentamycin  (Schering 
Corporation Ltd., Pointe Claire, Quebec) in a concentration of 100 ~g/ml was routinely added to 
prevent mycoplasma contamination. Cells were cultured in a  concentration of 106 cells/ml, and 
generally 5-10  ×  107 cells were used per culture. 
Radiolabeling of Cultured Marrow Cells.  Cultures were labeled continuously with [14C]uridme 
and  either  [3H]glucosamine or  [3H]leucine  using  a-medium lacking ribonucleotides alone,  or 
ribonucleotides and leucine. ['4C]uridine (540 mCi/mmol) was used at 1 ~Ci/ml, [3H]glucosamine 
(12 Ci/mmol) at 50 ~Ci/ml, and [3H]leucine (58 Ci/mmol) at 50 ~tCi/ml;  all three were purchased 
from the Radiochemical Centre, Amersham, England. 
Preparation  of Labeled  or  Unlabeled  Subcellular Fractions.  Culture  supernates separated 
from cells by centrifugation at 500 g  for 10 min were spun at 12,000 g  for 10 min. The resultant 
pellets were discarded and the supernates sedimented at 100,000 g  for 1 h  over a  cushion of 25% 
sucrose in TNE (0.05 M Tris, pH 7.5,  0.1 M Nacl, 1 mM EDTA). The sediments were resuspended 
in 1 ml of TNE, layered over 10 ml of a 20-70% linear sucrose gradient, and centrifuged for 16-18 h 
at 150,000 g  in an SW 41 rotor. 20 fractions were collected, and a  10 ~tl aliquot from each fraction 
was counted in 10 ml of Aquasol (New England Nuclear, Boston, Mass.) in a  Beckman LS-230 
scintillation counter. Fractions of densities 1.20-1.24  g/ml and 1.15-1.19 g/ml were collected in two 
separate pools, diluted in TNE,  and then pelleted at  150,000 g  for 1 h.  The final pellets were 
resuspended in TNE.  Protein concentration was determined by the method of Lowry et al.  (15). 
Unlabeled marrow isolates were prepared similarly without the addition of radioactivity in the 
cultures. 
Radioimmunoprecipitation  Assay (RIPA).  The assay was carried out as described by Ihle et 
al. (16). Labeled marrow material was diluted in TNE to give about 5,000 cpm of~H or 1,000 cpm of 
14C (1-2 ~g protein) per 0.05 ml per test. 0.2 ml of serial twofold dilutions of test serum were added 
and incubated for 1 h at 37°C. Subsequently, 0.2 ml of a 1:2 dilution of goat anti-human IgG (Meloy 
Laboratories, Springfield, Va.) was added, and the mixture was again incubated at 37°C for 1 h, 
then at 4°C overnight. All antiglobulins used were tested by immunoelectrophoresis and gave 
single precipitin lines. 
After the overnight incubation, supernates were separated from precipitates by centrifugation 
at 1,200 g  for 10 min and counted in 10 ml of Aquasol. Precipitates were washed three times in a 
total of 5 ml of TNE and then resuspended in 0.4  ml of TNE and counted in 10 ml of Aquasol. 
Precipitation was expressed as the percentage of counts in the precipitate relative to the combined 
counts in the precipitate and first supernate. In a preparation containing both 3H and '4C labels, 
the percentage precipitation of the 3H  counts was the same as that of the 14C  counts. As the 
efficiency of labeling with [3H]leucine/[3H]glucosamine was much higher than with [J4C]uridine, 
dilutions of labeled marrow material were made according to total 3H counts alone. 
The maximum precipitable radioactivity varied from one preparation of radiolabeled material 
to  another;  the  range  of variations  was  from  40  to  70%  of input  radioactivity.  For  a  given 
preparation, the titer of a positive serum was equal to the highest serum dilution that caused 50% 
precipitation of the maximum precipitable radioactivity, and all sera giving 50% precipitation or 
above were considered positive. For example, for the preparations derived from patient R, which 
were used for the titration studies reported in this paper, the maximum precipitable radioactivity 
was approximately 70% of input. Thus, the end point for all sera titrated using these preparations 
was precipitation of 0.5  x  70  =  35% of input radioactivity. 
Preparation of  Immune Precipitates for SDS-Polyacrylamide Gel Electrophoresis.  About 60,000 
cpm of [~H]leucine- or [~H]glucosamine-labeled  marrow material was precipitated by a dilution of 
serum giving maximum precipitation, as described above.  Unbound counts were disrupted by 
incubating the precipitate for 1 h at 4°C in 0.1 ml of buffer containing 1.2 M KCI, 1% Triton X-100, 
0.03 M fl-mercaptoethanol, and 0.1 M Tris, pH 7.5. The precipitate was then washed three times in 
TNE, solubilized in 8 M urea, 1% SDS, and 2% ~-mercaptoethanol in 0.1 M Tris, pH 8.6, heated to 
56°C for 30 min, and then to 100°C for 2 min before electrophoresis. S.  LOUIE,  J.  E.  CURTIS,  J.  E.  TILL,  AND  E.  A.  McCULLOCH  1245 
SDS-Polyacrylam~de  Gel Electrophoresls  of Labeled  Marrow  Materml and Immune Precipi- 
tates  SDS-polyacrylamide gel electrophoresls (7 5% gels) was done by the method of Weber and 
Osborne (17)  Labeled marrow material (about 40,000  cpm) was heated to 100°C for 2 mm in 2% 
SDS and 2%  fl-mercaptoethanol before electrophoresis. Immune precipitates were prepared as 
described above. The gels were run for 3-4 h at a constant current of  3 mA per gel. After fixation m 
10% trichloroacetic acid overnight, they were cut into 1-mm slices, eluted m 0 8 ml of a mixture of 
rune parts of NCS tmsue solubdlzer (Amersham/Searle Corporation, Arlington Heights, Ill ) to 
one part of water at 50°C for 2 h,  and then counted m  10  ml of toluene plus Llqmflour (New 
England Nuclear). 
[3H]leucine-labeled  M4  virus  was  run  in  separate  gels  [~4C]leucine-labeled M4  virus  was 
coelectrophoresed with 3H-labeled marrow material or immune precipitates. 
Marker proteins (bowne serum albumin,  ovalbumln, chymotrypsmogen, and cytochrome c) 
were run m  separate gels and stained m  Coomassie Blue. 
Results 
Sucrose  Density  Gradient  Analysts  of Labeled  Marrow  Culture  Super- 
nates.  To test whether radiolabeled material from marrow culture supernates 
was associated with particles similar to those reported previously (12), cultures 
labeled with [~4C]uridine  and either [3H]leucine or [3H]glucosamine were ana- 
lyzed by sucrose density gradient centrifugation. Typical results are shown in 
Fig.  1.  [~4C]uridine  generally  peaked  at  a  density  of  1.23 g/ml,  whereas 
[3H]leucine or [3H]glucosamine peaked at 1.17 g/ml. A similar pattern of label- 
ing was seen in cultures of 12 AML (9 relapse, 3 remissions), 5 ALL (2 relapse, 3 
remission),  2 CGL (relapse),  1 erythroleukemia (relapse),  and 7 nonleukemic 
marrows  (1  each  from  patients  with  iron  deficiency anemia,  megaloblastic 
anemia,  benign hyperglobulinemia, bronchogenic carcinoma,  prostatic carci- 
noma, plasmacytoma, and perihemangiocytoma). The only instances of failure 
to  label  were  two  consecutive marrow  samples from a  patient with  chronic 
lymphocytic leukemia. 
In preliminary experiments, reverse transcriptase activity was not observed 
in  culture  supernates  from  marrows  cultured  in  either  leucine-deficient or 
ribonucleotide and leucine-deficient media. Because it was technically difficult 
to assay for reverse transcriptase activity in culture supernates labeled with ~4C 
and 3H, the enzyme was not assayed in most of the experiments reported in this 
paper. 
RIPA.  To  test for the  presence  in human sera  of antibodies against the 
particles released by cultures of human marrow, radiolabeled material from 
culture supernates was prepared from appropriate sucrose density regions, and 
a RIPA was carried out as described in Materials and Methods. 
SELECTION OF  LABELED ANTIGEN.  In preliminary experiments a comparison 
was made between labeled material of densities of 1.20-1.24  g/ml and 1.15-1.19 
g/ml as antigen in RIPA.  With the same positive serum, the higher density 
material was usually more reactive than the lower density material, in terms of 
both maximal precipitation and titer.  Reaction patterns of the lower density 
material were often overshadowed by HL-A reactivity, as judged by reactions 
with sera of known anti-HL-A activity. For this reason, material pooled from 
the 1.20-1.24 g/ml region was used routinely in the assay. 
TITRATION CURVES.  A  typical titration curve  is  shown in Fig.  2.  With a 
constant amount of added anti-IgG (760 ~g), most human sera gave maximal 
precipitation at a  dilution of 1:32 or  1:64. Up to a  dilution of 1:256 or  1:512, 1246  ANTIBODIES  TO  RNA  VIRUS-LIKE  PROTEINS  FROM  HUMAN  MARROWS 
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FiG  1.  Density distribution  of radIolabeled material  from marrow culture  supernates: 
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FIG  2.  Titration curves of human serum and purified IgG: (O--O) normal human serum, 
(©---O) 25  ~g of IgG myeloma protein  added per dilution  from 1.256 on; (X--X) pooled 
normal human IgG; (A--&) and (A--A) IgG X-myeloma  proteins. 
precipitation  was  approximately  linear  with  dilution.  Beyond this,  a  carrier 
protein (one of two purified IgG X-myeloma proteins, see below) was required to 
give a  straight line end point titration. 
SPECIFICITY CONTROLS.  To rule out the possibility of nonspecific trapping in 
the assay, two purified human IgG X-myeloma proteins were used as controls; 
myeloma proteins were chosen because of their lack of antibody activity. Both 
myeloma  proteins  were  negative  in  the  precipitation  assay  (Fig.  2).  These 
served as negative controls, ruling out any significant nonspecific trapping and 
were suitable as carrier proteins in titration curves. In contrast, pooled normal S.  LOUIE,  J.  E.  CURTIS,  J.  E.  TILL,  AND  E.  A.  McCULLOCH  1247 
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FIG.  3.  Competition in RIPA with unlabeled antigen. Labeled antigen used in the assay 
was  obtained from  patient  R  (AML).  In control  assays,  50%  of total  radioactivity  was 
preclp~tated by serum A.J.  at a  dilution of 1:256.  Th~s dilution of A.J.  serum  was then 
prelncubated with twofold  dilutions of cold antigen  (horizontal ax~s),  and the resulting 
precipitation was expressed as a  percentage of the control  (vertical axis).  Cold antigens 
used: SSV ([~--[~), RLV (m--m), and unlabeled marrow supernatant material from patmnt 
Edi (ALL) (0, ©) and patmnt Rus (iron deficmncy) (A,/x). Marrow supernatant material of 
denmty 1.20-1.24, dashed hne; density 1.15-1 19, solid hne. 
human IgG gave a  positive precipitation curve.  Thus, it is unlikely that the 
presence of contaminating materials that are not themselves immunoglobulins 
can account for the results of RIPAs carried out using unpurified human sera. 
A second specificity control was competitive inhibition with unlabeled antigen 
(Fig. 3).  In these experiments, the percentage precipitation of labeled marrow 
material by a test serum was determined initially. This control value was used 
as 100% in normalization of data in Fig. 3. The same serum dilution was then 
preincubated with twofold dilutions of unlabeled marrow material for 1 h at 37°C 
before RIPA. We used unlabeled marrow material from both 1.20-1.24  g/ml and 
1.15-1.19  g/ml density regions in competition experiments. The higher density 
material was found to  contain more competing antigen.  Unlabeled material 
from nonleukemic marrows inhibited precipitation of labeled leukemic marrow 
material,  and the reverse  was also observed.  These results indicate that the 
antigen-antibody reaction is specific and is capable of competitive inhibition by 
similar density material from other marrows. All marrows tested were readily 
cross-reactive. 
Antigenic Competition  between Culture  Supernates  and Known Oncornavi- 
ruses.  To determine whether material prepared from human marrow culture 
supernates contained determinants cross-reactive with mammalian RNA tumor 
viruses, purified RNA tumor viruses were used as cold antigen to compete in the 
RIPA. As shown in Fig. 3,  when RLV or SSV-1/NC37  was used as competing 
antigen, much less inhibition was observed, even at high viral protein concen- 
trations, than with unlabeled human marrow material.  Similar results were 
obtained  with  intact  virus  or  virus  disrupted  by  10  cycles  of freezing  and 
thawing. The extent of cross-reactivity demonstrated in these experiments was 
slight and at the border of the sensitivity of the method. 
Analysis of Precipitated  Proteins  by SDS Polyacrylamide  Gel Electrophore- 1248  ANTIBODIES  TO  RNA  VIRUS-LIKE  PROTEINS  FROM  HUMAN  MARROWS 
sis.  Before precipitation the 1.20-1.24 g/ml density marrow material contained 
a heterogeneous collection of polypeptides (Fig. 4a). Upon precipitation with a 
reactive human serum (Fig. 4 b) the pattern resolved into one containing three 
distinct polypeptide peaks of approximately 70,000, 45,000, and 30,000 mol wt, as 
determined by reference to marker proteins or by coelectrophoresis with labeled 
M4  virus  (Fig.  4c).  Similar patterns  were  obtained from  15  leukemic and  5 
nonleukemic marrow culture supernates. 
To determine whether any of these polypeptides were glycopeptides, marrow 
culture material labeled  with  [3H]glucosamine was precipitated and the  im- 
mune  precipitate  analyzed  by  SDS-polyacrylamide  gel  electrophoresis.  As 
shown in Fig. 5, the 70,000 and 45,000 mol wt polypeptides were glycopeptides. 
These comigrated with the glycoproteins (gp 70 and gp 45) of M4 virus. 
Antibodies in Human Sera as Determined by RIPA.  45 sera from leukemic 
patients, 45 sera from normal donors, 19 sera from family contacts of leukemic 
patients,  21  normal  cord  blood  specimens,  and  23  sera  from  patients  with 
systemic lupus erythematosus (SLE) were tested for reactivity against radiola- 
beled  material  from  culture  supernates.  Reactivity was  demonstrated  in  a 
majority of these, and all positive sera precipitated autologous antigen, when 
available. As shown in Table I, 71% of leukemic sera, 80% of  normal sera, 79% of 
family contacts,  and  67%  of cord  blood  specimens  had  detectable  antibody 
activity.  There  was  no  significant difference  in  the  incidence  and  titer  of 
antibody between leukemic patients in relapse and those in remission (data not 
shown). 11 leukemic patients over a period of 12 mo (in and out of  remission) and 
4  normal laboratory workers  (2  positive and 2  negative for antibody) over a 
period of 6 mo showed no change in antibody titer.  Lupus patients stood out 
above the others;  21  out of 23  (91%) had detectable antibody activity. Fig.  6 
shows the titers of all sera tested. There is no significant difference between the 
mean titers of the leukemic, normal, family contact, or cord blood subgroups. 
However, the mean for the SLE sera is significantly higher than the means of 
each of the other subgroups on the basis of a t test (P <  0.01). When the mean 
titers of only the positive sera were compared, the mean for the positive SLE 
sera was again significantly higher than the means of the positive sera in the 
other subgroups (P  <  0.01). 
Discussion 
Our results  indicate that:  (a)  proteins similar in  molecular weight to the 
major envelope and internal proteins (gp 70, gp 45, p 30) of mammalian C-type 
RNA viruses can be  obtained from normal or  leukemic human marrow cell 
cultures and (b) antibodies reactive with one or more of  these antigens are found 
in many individuals, regardless of clinical status.  The first observation is in 
keeping with the findings of Strand and August (7) and Metzgar et al.  (8) who 
demonstrated the presence  of gp 67/71 and p  30-like proteins in a  variety of 
diseased and normal human cells. However, our experiments demonstrated only 
slight,  if any,  cross-reactivity between  these  proteins  from human  marrow 
culture supernates and murine and simian leukoviruses (see Fig. 3). 
It  should  be  noted  that  while  these  proteins  coprecipitate  with  material 
incorporating [14C]uridine  (presumably RNA), we have no additional evidence 30 
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FIG. 4.  SDS polyacrylamide gel electrophorems  patterns of [3H]leuclne-labeled marrow 
material  from patient  Van  (ALL): (a)  before  prec,pitatlon;  (b)  after preclpitatmn by 
autologous  serum  (0--{})  and  negative human serum J.N  (O--O);  (c)  precipitate by 
autologous  serum  (O--O) coelectrophoresed  with  [~4C]leucme-labeled M4 virus  (e--O). 
Arrows mdmate molecular weight in thousands 
to indicate that they are associated with virally related particles.  It is possible 
they represent cellular proteins with  antigenicities "unmasked" by the culture 
and preparative procedures.  Further  work is required to determine if they are 
truly related to known viral proteins. 1250  ANTIBODIES  TO  RNA  VIRUS-LIKE  PROTEINS  FROM  HUMAN  MARROWS 
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Fro. 5.  SDS-polyacrylamide gel electrophoresis patterns of: (a)  [3H]glucosamine-labeled 
M4 virus;  (b)  pH]glucosamine-labeled marrow material from patient Zaf (AML)  before 
(lower panel) and after  (upper panel) precipitation by positive human  serum C.C.;  (c) 
PH]glucosamine-labeled marrow material from patient Rus (iron deficiency anemia) before 
(lower panel) and after (upper panel) precipitation by serum A.J. 
Nonetheless, the presence in human sera  of antibodies with specificity for 
viral-like proteins is not unexpected. Precedence for this phenomenon is seen in 
mice, in which naturally occurring antibody to murine leukemia virus is de- 
tected in virtually all inbred strains (18). Anti-viral antibodies are also detected S.  LOUIE,  J.  E.  CURTIS,  J.  E.  TILL,  AND  E.  A.  McCULLOCH  1251 
TABLE  I 
The Incidence in Human Sera of Antibodies to RNA Tumor Virus-Like Proteins 
Obtained From Human Marrow Culture Supernates 
Sera  No. with antibody (total  Percent positive for  Mean titer (Log2) 
tested)  antibody 
Leukemic  32/45  71  4.7 
Normal  36/45  80  5.2 
Family contacts  15/19  79  5.2 
Cord blood  14/21  67  4.8 
Lupus  21/23  91  7.3 
12  Leukemic  Normal  Fomdy  Cord  Lupus 
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FIG.  6.  Titers of all human sera tested against labeled marrow material from patient R 
(AML). Family = family contacts of leukemic patients; cord = cord blood specimens; lupus 
=  sera from patients with SLE.  Vertical bars represent geometric mean titers of all sera 
tested. 
in cats (19) and gibbons (20); in the latter cases antibodies are more common in 
colonies with  an  incidence of leukemia or  lymphoma.  We  have  followed 11 
leukemic patients over a period of 12 mo, in and out of remission; none of them 
showed a  change in antibody titer.  Similarly, four normal laboratory workers 
showed no change in antibody titer over 6 mo. The relevance, if any, of this vi- 
rus-like information and immune response to human leukemia is unclear. 
Of special interest in this regard are patients with SLE. As a group, they show 
a  significantly higher mean antibody titer.  This is in accord with the recent 
report by Mellors and Mellors (21) of the presence of p 30-like antigen in human 
lupus kidneys, and may reflect one of the underlying pathogenic mechanisms in 
this disease. 
Summary 
Some  human  marrows  in  culture release  particles  with  oncornavirus-like 
properties. This study was designed to examine the immunological properties of 1252  ANTIBODIES  TO  RNA  VIRUS-LIKE  PROTEINS  FROM  HUMAN  MARROWS 
similar particles in human  marrow culture supernates.  Leukemic and nonleu- 
kemic marrows were cultured  for 5-7 days in the presence of [~4C]uridine  and 
[3H]leucine  or  [3H]glucosamine.  Labeled  supernatant  components banding  in 
sucrose  gradient  densities  of 1.20-1.24  g/ml were used  as antigen  in a  double 
antibody  immunopyecipitation  assay.  The  assay  was  validated  by  end  point 
titrations  and  competition with  unlabeled  antigen;  purified myeloma proteins 
were  used  as  negative  controls.  Cross-reactivity with  mammalian  oncornavi- 
ruses, as judged by competitive inhibition of precipitation by these viruses, was 
slight and at the border of the sensitivity of the method.  Precipitated antigens 
analyzed  by  SDS  polyacrylamide gel  electrophoresis  contained  three  distinct 
polypeptides of about 70,000,  45,000  and 30,000  mol wt;  these  comigrated with 
the gp 70, gp 45, and p 30 of a murine leukemia virus. Similar polypeptides were 
obtained from both leukemic and nonleukemic marrow culture supernates.  As 
determined  by  the  radioimmunoprecipitation  assay,  32  of 45  leukemic  sera 
(71%), 36 of 45 normal sera (80%),  15 of 19 sera from family contacts of leukemic 
patients (79%), 14 of 21 cord blood specimens (67%), and 21 of 23 sera (91%) from 
patients with systemic lupus erythematosus had detectable antibody activity. 
We  wish  to  thank  Mr.  N.  Jamal  for  excellent  technical  assistance;  Dr.  J.  S.  Senn  of the 
Sunnybrook Medical Centre,  Toronto, for providing some of the bone marrows and sera used; Dr. 
M.  Urowitz  of the  Wellesley  Hospital,  Toronto,  for  providing  all  of the  lupus  sera;  Dr.  B. 
Underdown,  Institute of Immunology, University of Toronto,  for providing  the pooled normal 
human IgG and purified IgG myeloma proteins; Dr. A. Howatson, the Ontario Cancer Institute, 
for providing the radio-labeled  M4 virus; and Dr. R. Phillips,  the Ontario Cancer Institute, for his 
valuable advice. 
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